TNF and cancer: This chemokine/cytokine milieu is well‐known to be a central modulator of the cancer microenvironment and it has been established as one of the hallmark drivers of cancer.46 Among these prominently downregulated chemokines and cytokines upon ruxolitinib treatment, we found ll6, Tnfα and Cxcl1. All of them are well‐described pro‐inflammatory and pro‐tumorigenic chemo‐ and cytokines.